Bupropion hydrochloride; naltrexone hydrochloride - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for bupropion hydrochloride; naltrexone hydrochloride and what is the scope of patent protection?
Bupropion hydrochloride; naltrexone hydrochloride
is the generic ingredient in one branded drug marketed by Nalpropion and is included in one NDA. There are twenty patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.Bupropion hydrochloride; naltrexone hydrochloride has two hundred and sixty-nine patent family members in forty-four countries.
One supplier is listed for this compound.
Summary for bupropion hydrochloride; naltrexone hydrochloride
International Patents: | 269 |
US Patents: | 20 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 46 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for bupropion hydrochloride; naltrexone hydrochloride |
DailyMed Link: | bupropion hydrochloride; naltrexone hydrochloride at DailyMed |
Recent Clinical Trials for bupropion hydrochloride; naltrexone hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of California, Los Angeles | Early Phase 1 |
Nederlandse Obesitas Kliniek | Phase 4 |
Zuyderland Medisch Centrum | Phase 4 |
See all bupropion hydrochloride; naltrexone hydrochloride clinical trials
Pharmacology for bupropion hydrochloride; naltrexone hydrochloride
Drug Class | Aminoketone Opioid Antagonist |
Mechanism of Action | Dopamine Uptake Inhibitors Norepinephrine Uptake Inhibitors Opioid Antagonists |
Physiological Effect | Increased Dopamine Activity Increased Norepinephrine Activity |
Anatomical Therapeutic Chemical (ATC) Classes for bupropion hydrochloride; naltrexone hydrochloride
Paragraph IV (Patent) Challenges for BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
CONTRAVE | Extended-release Tablets | bupropion hydrochloride; naltrexone hydrochloride | 8 mg/90 mg | 200063 | 1 | 2015-03-12 |
US Patents and Regulatory Information for bupropion hydrochloride; naltrexone hydrochloride
Expired US Patents for bupropion hydrochloride; naltrexone hydrochloride
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Nalpropion | CONTRAVE | bupropion hydrochloride; naltrexone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 200063-001 | Sep 10, 2014 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for bupropion hydrochloride; naltrexone hydrochloride
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Korea | 20150082689 | 단위 용량 팩키지 (UNIT DOSAGE PACKAGES) | ⤷ Try a Trial |
South Korea | 20060009871 | COMPOSITIONS FOR AFFECTING WEIGHT LOSS | ⤷ Try a Trial |
Taiwan | I661826 | ⤷ Try a Trial | |
Japan | 2013047272 | COMPOSITION AND METHOD FOR INCREASING INSULIN SENSITIVITY | ⤷ Try a Trial |
Russian Federation | 2009116834 | СПОСОБ ВВЕДЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ ДЛЯ СНИЖЕНИЯ ВЕСА | ⤷ Try a Trial |
Chile | 2007003245 | COMPOSICION FARMACEUTICA EN CAPA QUE COMPRENDE DOS O MAS CAPAS FARMACEUTICAS Y AL MENOS UNA CAPA INTERMEDIA DISPUESTA ENTRE AL MENOS DOS O MAS CAPAS, DONDE LA CAPA INTERMEDIA ES CONFIGURADA PARA DISOLVERSE IN VIVO DONDE DICHAS DOS CAPAS FARMACEUTICAS | ⤷ Try a Trial |
Japan | 6665094 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for bupropion hydrochloride; naltrexone hydrochloride
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0467488 | SPC/GB00/019 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: BUPROPION HYDROCHLORIDE; REGISTERED: NL RVG 24160 19991201; UK PL 10949/0340 20000607 |
2316456 | 65/2017 | Austria | ⤷ Try a Trial | PRODUCT NAME: NALTREXON ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE NALTREXONHYDROCHLORID, UND BUPROPION ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE BUPROPIONHYDROCHLORID; REGISTRATION NO/DATE: EU/1/14/988 (MITTEILUNG) 20150330 |
2316456 | 657 | Finland | ⤷ Try a Trial | |
2316456 | 17C1058 | France | ⤷ Try a Trial | PRODUCT NAME: NALTREXONE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER CHLORHYDRATE DE NALTREXONE ET,BUPROPION OU SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER CHLORHYDRATE DE BUPROPION; REGISTRATION NO/DATE: EU/1/14/988 20150330 |
2316456 | 2017/059 | Ireland | ⤷ Try a Trial | PRODUCT NAME: NALTREXONE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR NALTREXONE HYDROCHLORIDE, AND BUPROPION OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BUPROPION HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/14/988 20150326 |
2316456 | 349 22-2017 | Slovakia | ⤷ Try a Trial | PRODUCT NAME: KOMBINACIA NALTREXONU VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM A BUPROPIONU VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/14/988 20150330 |
2316456 | 122017000109 | Germany | ⤷ Try a Trial | PRODUCT NAME: NALTREXON ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE NALTREXONHYDROCHLORID, UND BUPROPION ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE BUPROPIONHYDROCHLORID; REGISTRATION NO/DATE: EU/1/14/988 20150326 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.